<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30371238</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">2047-9980</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>7</Volume>                    <Issue>15</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>07</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of the American Heart Association</Title>                <ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation>            </Journal>            <ArticleTitle>Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction.</ArticleTitle>            <Pagination>                <MedlinePgn>e008637</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.118.008637</ELocationID>            <Abstract>                <AbstractText>Background Trastuzumab is life-extending therapy for breast cancer patients overexpressing the human epidermal growth factor receptor 2 ( HER 2+), but has known cardiotoxic risk. We sought to determine if trastuzumab can be administered to patients with reduced baseline cardiac function at no higher cardiotoxicity risk than in those with normal cardiac function at baseline. Methods and Results We performed a retrospective study of women treated with trastuzumab for human epidermal growth factor receptor 2 breast cancer at Mayo Clinic Rochester between January 1, 2000 and August 31, 2015 with pre- and on-therapy echocardiograms available for review. A left ventricular ejection fraction (LVEF) &lt;53% was considered abnormal, and a ≥10% decline in LVEF as evidence of cardiotoxicity based on the criteria of the American Society of Echocardiography. A total of 428 women were identified; 408 had a normal cardiac function ( LVEF 63.4±5%) and 20 had an impaired cardiac function ( LVEF 45.4±7%) before trastuzumab. Seven women (35%) with reduced LVEF at baseline had a ≥10% reduction in LVEF , compared with 179 (43.9%) of those with normal LVEF before trastuzumab initiation ( P= NS ). Symptomatic heart failure developed more often in patients with reduced versus normal baseline LVEF (25% versus 4.2%, P&lt;0.05). After adjusting for patient age and breast cancer disease stage, survival rates over 5 years from time of diagnosis were found to be lower for patients with reduced baseline LVEF compared with patients with normal baseline LVEF ( P&lt;0.001); the adjusted proportion of patients surviving at 5 years for those with low LVEF at baseline was 79% and for those with normal LVEF was 93%. Conclusions Women undergoing trastuzumab therapy for breast cancer with impaired baseline cardiac function experience no higher risk of LVEF decline, but more frequently develop symptomatic heart failure. While trastuzumab could be considered, these patients should be co-managed by a cardiologist.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Nowsheen</LastName>                    <ForeName>Somaira</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>1 Mayo Clinic School of Medicine Mayo Clinic Rochester MN.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Aziz</LastName>                    <ForeName>Khaled</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>1 Mayo Clinic School of Medicine Mayo Clinic Rochester MN.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Park</LastName>                    <ForeName>Jae Yoon</ForeName>                    <Initials>JY</Initials>                    <AffiliationInfo>                        <Affiliation>2 Department of Cardiovascular Medicine Mayo Clinic Rochester MN.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lerman</LastName>                    <ForeName>Amir</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>2 Department of Cardiovascular Medicine Mayo Clinic Rochester MN.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Villarraga</LastName>                    <ForeName>Hector R</ForeName>                    <Initials>HR</Initials>                    <AffiliationInfo>                        <Affiliation>2 Department of Cardiovascular Medicine Mayo Clinic Rochester MN.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ruddy</LastName>                    <ForeName>Kathryn Jean</ForeName>                    <Initials>KJ</Initials>                    <AffiliationInfo>                        <Affiliation>3 Division of Medical Oncology Mayo Clinic Rochester MN.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Herrmann</LastName>                    <ForeName>Joerg</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>2 Department of Cardiovascular Medicine Mayo Clinic Rochester MN.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>J Am Heart Assoc</MedlineTA>            <NlmUniqueID>101580524</NlmUniqueID>            <ISSNLinking>2047-9980</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2016 Feb 20;34(6):581-7</RefSource>                <PMID Version="1">26392097</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2007 Jan 6;369(9555):29-36</RefSource>                <PMID Version="1">17208639</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2005 May 1;23(13):2900-2</RefSource>                <PMID Version="1">15860848</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2012 Nov 1;30(31):3792-9</RefSource>                <PMID Version="1">22987084</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Circulation. 2013 Oct 15;128(16):1810-52</RefSource>                <PMID Version="1">23741057</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2005 Oct 20;353(16):1659-72</RefSource>                <PMID Version="1">16236737</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2002 Mar 1;20(5):1215-21</RefSource>                <PMID Version="1">11870163</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Coll Cardiol. 2010 Nov 9;56(20):1644-50</RefSource>                <PMID Version="1">21050974</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur Heart J. 2016 Jul 14;37(27):2129-2200</RefSource>                <PMID Version="1">27206819</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2014 Jul 10;32(20):2159-65</RefSource>                <PMID Version="1">24912899</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mayo Clin Proc. 2014 Sep;89(9):1287-306</RefSource>                <PMID Version="1">25192616</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mayo Clin Proc. 2008 Feb;83(2):197-203</RefSource>                <PMID Version="1">18241629</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 1987 Jan 9;235(4785):177-82</RefSource>                <PMID Version="1">3798106</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anticancer Res. 2013 Apr;33(4):1717-20</RefSource>                <PMID Version="1">23564821</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur Heart J Cardiovasc Imaging. 2014 Oct;15(10):1063-93</RefSource>                <PMID Version="1">25239940</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2005 Oct 20;353(16):1673-84</RefSource>                <PMID Version="1">16236738</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2017 Mar 25;389(10075):1195-1205</RefSource>                <PMID Version="1">28215665</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2002 Oct 1;95(7):1592-600</RefSource>                <PMID Version="1">12237930</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cardiol. 2010 Oct;7(10):564-75</RefSource>                <PMID Version="1">20842180</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA Oncol. 2016 Jan;2(1):29-36</RefSource>                <PMID Version="1">26539793</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2011 Mar;12(3):236-44</RefSource>                <PMID Version="1">21354370</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Heart Assoc. 2014 Feb 28;3(1):e000472</RefSource>                <PMID Version="1">24584736</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2014 Nov 20;32(33):3744-52</RefSource>                <PMID Version="1">25332249</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cardiol. 2015 Sep;12(9):547-58</RefSource>                <PMID Version="1">25962976</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2010 Sep 1;28(25):3910-6</RefSource>                <PMID Version="1">20679614</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37</RefSource>                <PMID Version="1">11252954</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Heart. 2013 May;99(9):634-9</RefSource>                <PMID Version="1">23349345</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2004 May;4(5):361-70</RefSource>                <PMID Version="1">15122207</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2001 Mar 15;344(11):783-92</RefSource>                <PMID Version="1">11248153</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 1999 Sep;17(9):2639-48</RefSource>                <PMID Version="1">10561337</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Circulation. 2017 Apr 11;135(15):1397-1412</RefSource>                <PMID Version="1">28104715</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trends Cardiovasc Med. 2014 Oct;24(7):285-95</RefSource>                <PMID Version="1">25153017</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2014 Jan;25(1):276-82</RefSource>                <PMID Version="1">24356639</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2007 May;7(5):332-44</RefSource>                <PMID Version="1">17457301</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Card Fail. 2008 Jun;14(5):437-44</RefSource>                <PMID Version="1">18514938</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2015 Feb 19;372(8):724-34</RefSource>                <PMID Version="1">25693012</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Echocardiography. 2014;31(1):87-100</RefSource>                <PMID Version="1">24786629</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">HER2</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">cardiomyopathy</Keyword>            <Keyword MajorTopicYN="N">cardiotoxicity</Keyword>            <Keyword MajorTopicYN="N">chemotherapy</Keyword>            <Keyword MajorTopicYN="N">heart failure</Keyword>            <Keyword MajorTopicYN="N">left ventricular ejection fraction</Keyword>            <Keyword MajorTopicYN="N">trastuzumab</Keyword>            <Keyword MajorTopicYN="N">treatment</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30371238</ArticleId>            <ArticleId IdType="doi">10.1161/JAHA.118.008637</ArticleId>            <ArticleId IdType="pmc">PMC6201446</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>